AbbVie Inc.

ABBV

210.01 (-0.92%) 1.93

370.74(B)

Health Care

Biotechnology

AbbVie Inc. a research-based biopharmaceutical company engages in the research and development manufacture commercialization and sale of medicines and therapies worldwide. The company offers Humira an injection for autoimmune and intestinal Behçet's diseases generalized pustular psoriasis and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases erythrodermic psoriasis generalized pustular psoriasis and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables plastics and regenerative medicine body contouring and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia bipolar disorder and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine as well as other neuroscience products. In addition the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago Illinois.

Holdings:

Cost basis:

Valuation Overview Growth Estimates Per Share Data Similar Companies Historical Data Calculators

AbbVie Inc. (ABBV) price target and intrinsic value estimate

ABBV's fair price estimate is $177.7

This valuation is based on a fair P/E of 13.9 and EPS estimates of $12.74

The median analyst price target for ABBV is $214.0.

Analyst price targets range from $173.0 to $250.0

Is ABBV overvalued or undervalued?

ABBV is currently trading at $210.01

ABBV is overvalued by 18% using the pevaluation method.

ABBV is undervalued by 2% compared to median analyst price targets.

Do you agree with this valuation?

Access thousands of companies and create your own custom market model.
Claim your FREE account

Valuation

PEvaluation

Current price

$210

Fairly valued

Low

$133

Median

$178

High

$222

Fair P/E

Margin of safety

Analyst valuation

Current price

$210

Fairly valued

Low

$173

Median

$214

High

$250

Strong Buy5

Buy11

Hold10

Sell0

Strong Sell0

Discounted cash-flow

N/A
Negative FCF or FCF estimates

TTM FCFFCF est.Growth FCFTerminal FCF

Discount
rate10%

Terminal
rate5%

Growth p.
length5y

Growth p.
rate10%

Economic moat: Wide

Overview

Market data

Market cap:$370.74(B)

Enterprise value:$433.25(B)

Total Equity:$3.36(B)

Shares outstanding:1.77(B)

Div. yield:3.00%

P/S:6.59

P/E:87.50

P/FCF:20.79

P/B:111.71

EPS:$2.4

FCF per share:$10.1

Dividend per share:$6.3

Income (TTM)

Revenue$56.33(B)

Gross profit$39.61(B)

EBITDA$26.21(B)

Net income$4.28(B)

Gross margin70.3%

Net margin7.6%

Balance sheet

Total assets$135.16(B)

Total liabilities$131.80(B)

Cash & Short-term inv.$5.55(B)

Long-term debt$60.32(B)

Debt issued$21.97(B)

Debt repaid$-14.62(B)

Cash flow (TTM)

FCF$17.83(B)

CapEx$-974.00(M)

Dividends paid$-11.03(B)

Stock issued$214.00(M)

Stock repurchased$-1.71(B)

Stock-based comp.$1.42(B)

Per Share Data

Zoom x1

Show Growth

Growth Estimates

Revenue

CAGR: 6.5%

FY+1$59.36(B)

FY+2$64.21(B)

FY+3$68.70(B)

FY+4$72.88(B)

FY+5$76.42(B)

Net Income

CAGR: 9.7%

FY+1$21.81(B)

FY+2$24.55(B)

FY+3$27.33(B)

FY+4$29.49(B)

FY+5$31.61(B)

EPS

CAGR: 10.3%

FY+1$12.28

FY+2$13.88

FY+3$15.45

FY+4$16.87

FY+5$18.20

FCF per share

CAGR: 12.0%

FY+1$13.08

FY+2$14.28

FY+3$16.39

FY+4$18.75

FY+5$20.60

Similar Companies

Historical Financials

Showing limited histrical data. Access 10+ years of financials now! Upgrade

YearlyQuarterly

Income

RevenueOperating IncomeNet IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomePre-tax incomeIncome tax

Cash flow

Stock-based Comp.FCFCFONet IncomeD&ACFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures

Balance sheet

Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity

Per share data

EPS (Basic)FCF/ShareDividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share

Ratios

P/EP/SEV/EarningsP/FCFP/BEV/FCFDebt/EquityPayout ratio

Margins

Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin

Returns

ROICROAROCEROE

Shares outstanding

Shares (Basic)Shares (Diluted)

Market Cap.

Calculators

Future P/E valuation

Projection Years:

Base Revenue:

Revenue Growth Rate (%):

Final Net Margin (%):

Final P/E Ratio:

Discount Rate (%):

Graham formula

Earnings Per Share (EPS):

Expected Growth Rate (%):

Government Bond Rate (%):

Dividend discount model

Annual Dividend ($):

First Stage Length (Years):

First Stage Growth Rate (%):

Second Stage Growth Rate (%):

Discount Rate (%):